ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com
60 Degrees Pharmaceuticals, Inc. (SXTP) stock declined over -591.40%, trading at $1.75 on NASDAQ, down from the previous close of $1.86. The stock opened at $1.85, fluctuating between $1.75 and $1.91 in the recent session.
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Employees | 3 |
Beta | 4.54 |
Sales or Revenue | $253.57K |
5Y Sales Change% | -0.83% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |